Literature DB >> 3921614

Lymphokine-induced cytotoxicity: requirement of two lymphokines for the induction of optimal cytotoxic response.

S S Yang, T R Malek, M E Hargrove, C C Ting.   

Abstract

Lymphokines induce the generation of cytotoxic cells (LICC) in the absence of antigenic or mitogenic stimulation. In the present study, we have demonstrated that at least two lymphokines are involved. They are interleukin 2-conditioned medium (CM-IL 2), which was produced by W/Fu rat spleen cells cultured with concanavalin A-conjugated Sepharose beads, and cytotoxic cell differentiation factor-conditioned medium (CM-CCDF), which was produced primarily by the unstimulated mouse peritoneal macrophages. It was first established that CCDF synergized with IL 2 to induce the generation of LICC in normal spleen cells, and that this process was specifically blocked by the rat anti-IL 2 receptor monoclonal antibody. The maximal synergistic effect was obtained by using 10% CM-CCDF (v/v) and 0.1 to 0.3 U/ml of CM-IL 2. Higher doses of IL 2 (3 to 10 U/ml) reduced the cytotoxic response. The effectors of LICC were Thy-1+, Lyt-2- and AGM1-; therefore, they were neither classic CTL nor NK cells. The precursors were AGM1+, Lyt-2- cells that were consistent of being NK-like cells. When examining the temporal relationship between CCDF and IL 2, we found that 4 hr preincubation of the responders with IL 2 was sufficient to activate the cytotoxic precursor cells. CCDF was needed later for the differentiation of the activated precursors into cytotoxic effectors. In contrast, preincubation of the responders with CCDF, followed by additional incubation with IL 2, failed to induce any cytotoxic response. These results established that lymphokine-induced cytotoxicity can be separated into two phases. In the activation phase, IL 2 provides the first signal to activate the cytotoxic precursors, with the process being completed in 4 hr. In the differentiation phase, CCDF provides the second signal to induce the differentiation of the IL 2-activated precursors into cytotoxic effectors, with this process requiring 48 hr to complete. The sequential presence of these lymphokines at an appropriate time during the activation and differentiation phases is critical for the generation of LICC response.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3921614

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  11 in total

1.  Monocyte-dependent, serum-borne suppressor of induction of lymphokine-activated killer cells in lymphocytes from melanoma patients.

Authors:  K Itoh; N R Pellis; C M Balch
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

2.  Partial correction of defective generation of lymphokine-activated killer cells in patients with chronic myelogenous leukaemia after in vivo treatment with interferon-alpha (Wellferon).

Authors:  G Pawelec; E Schneider; G Ehninger; A Rehbein; H Schmidt
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

3.  Augmentative effect of Nocardia rubra cell-wall skeleton on the induction of human lymphokine-activated killer (LAK) cells by the production of LAK cell helper factor(s).

Authors:  T Shirasaka; I Kawase; M Okada; M Kitahara; T Ikeda; K Komuta; S Hosoe; S Yokota; T Masuno; S Kishimoto
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

4.  Inhibition by fibrin coagulation of lung cancer cell destruction by human interleukin-2-activated killer cells.

Authors:  S Atagi; S Sone; K Fukuta; T Ogura
Journal:  Jpn J Cancer Res       Date:  1992-10

5.  Interleukin-2-inducible killer activity and its regulation by blood monocytes from autologous lymphocytes of lung cancer patients.

Authors:  S Sone; E Kunishige; F Fawzy; H Yanagawa; A Nii; K Maeda; S Atagi; Y Heike; Y Nishioka; K Mizuno
Journal:  Jpn J Cancer Res       Date:  1991-06

6.  Induction by interleukin-15 of human killer cell activity against lung cancer cell lines and its regulatory mechanisms.

Authors:  E Takeuchi; H Yanagawa; S Yano; T Haku; S Sone
Journal:  Jpn J Cancer Res       Date:  1996-12

7.  Amelioration of B16F10 melanoma lung metastasis in mice by a combination therapy with indomethacin and interleukin 2.

Authors:  R S Parhar; P K Lala
Journal:  J Exp Med       Date:  1987-01-01       Impact factor: 14.307

8.  Inhibition of cytotoxic T cell development by transforming growth factor beta and reversal by recombinant tumor necrosis factor alpha.

Authors:  G E Ranges; I S Figari; T Espevik; M A Palladino
Journal:  J Exp Med       Date:  1987-10-01       Impact factor: 14.307

9.  Lymphokine-activated killer induction and its regulation by macrophages in malignant pleural effusions.

Authors:  H Yanagawa; S Sone; A Nii; K Fukuta; M Nakanishi; K Maeda; M Honda; T Ogura
Journal:  Jpn J Cancer Res       Date:  1989-12

10.  Enhancement by monocytes of perforin production and its gene expression by human CD8+ T cells stimulated with interleukin-2.

Authors:  K Sugihara; S Sone; M Shono; A Nii; M Munekata; K Okumura; T Ogura
Journal:  Jpn J Cancer Res       Date:  1992-11
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.